Cinnamon also shines in managing blood sugar. It enhances insulin sensitivity and regulates blood sugar by mimicking insulin. Studies confirm that cinnamon can reduce fasting blood sugar levels and improve long-term blood glucose markers​ (MDPI)​​ (MDPI)​.

How to Use:
1⃣ Ingredients: 1/4 tsp fenugreek seeds and half an inch of Ceylon cinnamon stick.
2⃣ Preparation: Soak both in regular water overnight.
3⃣ Usage: Drink the mixture on an empty stomach every morning.
4⃣ Duration: Follow this routine for 3 months while maintaining a balanced, low-GI diet.

Who Should Avoid:
Pregnant or breastfeeding women
Individuals with allergies to fenugreek or cinnamon
People on blood-thinning medications (consult your doctor first)

The post A 3000-Year-Old Cure for Modern Diabetes appeared first on MyMedicPlus.

Diabetes, particularly Type 1 diabetes, is a chronic condition where the body’s immune system mistakenly attacks insulin-producing beta cells in the pancreas. This has led to extensive research aimed at finding ways to regenerate these cells and restore normal insulin production. Recent advancements have shown significant promise in this area.

Regeneration of Beta Cells

1. Combination Drug Therapy: Recent studies by Mount Sinai and City of Hope have demonstrated that a combination of harmine and GLP1 receptor agonists can increase the number of insulin-producing beta cells by 700% within three months. This combination therapy, tested in diabetic mice, effectively reversed the symptoms of diabetes and maintained these improvements even after stopping the treatment​ (New Atlas)​​ (ColoradoBoulevard.net)​.
2. Inceptor Blockade: Researchers at Helmholtz Munich have identified a novel target, the inceptor receptor, which plays a crucial role in beta cell health. Blocking this receptor has shown potential in enhancing beta cell function and survival, providing a new avenue for diabetes treatment​ (SciTechDaily)​.
3. Stem Cell-Derived Islets: The Diabetes Research Institute has developed a combination therapy using iTOL-100 microgel and stem cell-derived islets. This approach has demonstrated success in restoring normoglycemia in diabetic models without the need for chronic immunosuppression, indicating a scalable and sustainable solution for Type 1 diabetes​ (InventUM)​.

Advances in Beta Cell Protection and Regeneration

1. EZH2 Inhibitors: Scientists at the Baker Heart and Diabetes Institute in Melbourne have explored the use of EZH2 inhibitors, such as GSK126 and Tazemetostat, to transform pancreatic ductal cells into insulin-producing beta cells. This method has shown the ability to produce insulin in response to glucose levels, offering a potential new treatment for Type 1 diabetes​ (Diabetes UK)​​ (JDRF)​.
2. Gene Editing Technologies: Ongoing research is utilizing CRISPR and other gene-editing tools to protect and regenerate beta cells. These technologies are being used to modify genes involved in beta cell growth and survival, aiming to enhance their function and resistance to autoimmune attacks.

Clinical Trials and Future Directions

1. Phase 1 Clinical Trials: Harmine, one of the drugs used in combination therapy, has undergone phase 1 clinical trials to assess its safety and tolerability in humans. The results have been promising, paving the way for further clinical trials with combinations of beta-cell-regenerating drugs and immune modulators​ (New Atlas)​.
2. Expanded Trials for VX-880: An experimental stem cell therapy using VX-880 has shown success in eliminating severe hypoglycemic events in patients with Type 1 diabetes. The trial has been expanded to include more participants, indicating a significant step towards potential approval and wider use​ (MedXpress)​.
3. Islet Transplantation: Advances in islet transplantation techniques, including the use of immunomodulatory microgels, have shown promise in restoring insulin production without the need for lifelong immunosuppression. This could significantly improve the quality of life for people with Type 1 diabetes​ (InventUM)​.

Economic and Social Impact

1. Economic Burden: The cost of diabetes management, including insulin therapy, medical visits, and complications, is substantial. Advances in beta cell regeneration could reduce these costs significantly by potentially eliminating the need for constant insulin administration and monitoring.
2. Social Consequences: The potential to cure or significantly alleviate Type 1 diabetes through beta cell regeneration would have profound social implications. It would improve the quality of life for millions of people, reduce the burden on healthcare systems, and allow individuals to lead more normal lives without the constant management of blood sugar levels.

Conclusion

The recent advancements in beta cell research for diabetes treatment are incredibly promising. From combination drug therapies to stem cell-derived islets and gene-editing technologies, these innovations have the potential to transform diabetes management and offer hope for a cure. Continued research, clinical trials, and collaboration among scientists and medical professionals are essential to bring these treatments from the lab to the clinic and ultimately to the patients who need them most.

These findings highlight the importance of ongoing investment in diabetes research and the potential for these new treatments to significantly impact global health.

The post New Research in Beta Cells for Diabetes Cure appeared first on MyMedicPlus.

Lowering blood sugar levels immediately requires a multifaceted approach that focuses on both short-term actions and long-term lifestyle changes. It’s important to note that these suggestions are general in nature and should not replace advice from a healthcare professional. If you’re experiencing consistently high blood sugar levels, it’s crucial to consult with a medical expert for personalized guidance. That being said, here are some actions you can consider:

Here are some things you can do to lower your blood sugar level immediately:

• Eat a sugary snack. This could be a piece of fruit, a hard candy, or glucose tablets. The sugar will help to raise your blood sugar levels quickly.
• Drink juice or soda. This will have the same effect as eating a sugary snack.
• Take a fast-acting insulin injection. This is only for people who have been diagnosed with diabetes and have been prescribed insulin.
• Exercise. Exercise can help to lower blood sugar levels by increasing the amount of glucose that is used for energy. However, it is important to talk to your doctor before exercising if your blood sugar levels are low.
• Go to the hospital. If your blood sugar levels are very low, you may need to go to the hospital. This is especially important if you are experiencing symptoms such as dizziness, confusion, or seizures.
• ay Hydrated: Drinking water can help flush excess sugar from your bloodstream through urine. Aim to stay well-hydrated throughout the day.
• Engage in Physical Activity: Physical activity can help your body use glucose more effectively. A brisk walk, light exercise, or even stretching can be beneficial. However, consult your doctor before starting any new exercise routine, especially if you have diabetes.
• Consume Fiber: Foods high in soluble fiber, like vegetables, whole grains, and legumes, can help stabilize blood sugar levels by slowing down the absorption of sugar. Avoid refined carbohydrates.
• Choose Low-Glycemic Foods: Opt for foods with a low glycemic index (GI) as they cause slower and steadier increases in blood sugar. Examples include whole fruits, non-starchy vegetables, and whole grains.
• Avoid Sugary Foods and Drinks: Steer clear of sugary snacks, desserts, and sugary drinks, as they can cause rapid spikes in blood sugar levels.
• Eat Protein-Rich Foods: Including protein in your meals can help regulate blood sugar levels. Lean sources of protein, like poultry, fish, tofu, and legumes, are good choices.
• Monitor Portion Sizes: Be mindful of portion sizes to avoid overeating, which can contribute to higher blood sugar levels.
• Manage Stress: Practice stress-reduction techniques such as deep breathing, meditation, or yoga, as stress hormones can impact blood sugar levels.
• Sleep Well: Aim for sufficient, quality sleep as lack of sleep can disrupt blood sugar regulation.
• Consider Apple Cider Vinegar: Some studies suggest that consuming a small amount of apple cider vinegar before meals might help improve insulin sensitivity and lower blood sugar levels. However, consult your doctor before trying this.
• Stay Away from Alcohol: Alcohol can cause blood sugar levels to drop initially and then rise later. It’s best to avoid it or consume it in moderation.
• Take Medications as Prescribed: If you’re on medication for diabetes, ensure you’re taking it as prescribed by your doctor.
• Check Your Blood Sugar: If you have a glucose meter, monitor your blood sugar levels as recommended by your healthcare provider. This will help you understand your current levels and track any improvements.

Here are some additional things you can do to help lower your blood sugar levels over the long term:

• Eat a healthy diet. This means eating plenty of fruits, vegetables, and whole grains. It also means limiting your intake of processed foods, sugary drinks, and unhealthy fats.
• Exercise regularly. Aim for at least 30 minutes of moderate-intensity exercise most days of the week.
• Manage your stress levels. Stress can raise blood sugar levels, so it is important to find healthy ways to manage stress.
• Take your medication as prescribed by your doctor. If you are taking medication for diabetes, it is important to take it as prescribed by your doctor.

Foods to Lower Your Blood Sugar

• Broccoli.
• Seafood.
• Pumpkin.
• Nuts.
• Okra.
• Flaxseed.
• Beans.
• Fermented foods.

The post How to Lower Blood Sugar Level Immediately? appeared first on MyMedicPlus.

A treasure-trove of nutrients, this winter vegetable has always been a popular choice for regulating blood sugar and managing diabetes.

• Green peas are used extensively in every kitchen across India
• It contains dietary fibre that helps slow down rise in our blood sugar
• Green pea pods are also deemed great for weight loss

It is that time of the year when our vegetable baskets are filled with fresh and crunchy green peas. Also called matar in Hindi, this fibrous vegetable is delicious and can be eaten in various forms. From nibbling it as is to adding to various winter-special recipes – green peas are used extensively in every kitchen across India. And what adds to its credits is the rich nutrient-profile. Green peas are loaded with vitamins, dietary fibre, protein, antioxidants etc that benefits our health in several ways.

Green Peas For Diabetes | Matar Health Benefits:

A treasure-trove of nutrients, this winter vegetable has always been a popular choice for regulating blood sugar and managing diabetes. It contains dietary fibre that helps slow down the rise in our blood sugar level. For the unversed, an earlier study found that eating more dietary fibre can boost a group of healthy gut bacteria that further helps prevent type-2 diabetes. The findings were published in the journal Science. As per experts, the low calorie and rich potassium content of green peas further help to keep a check on our blood sugar levels.

Alongside managing diabetes, these sweet and fibrous pea pods are also deemed great for weight loss, managing cholesterol levels and promoting bone health.

The post Green Pea For Diabetes: This Boiled Matar Chaat Can Be A Perfect Snack For The Diabetics appeared first on MyMedicPlus.

The post More than half of 20-year-olds in India’s metros likely to develop diabetes in lifetime: Study appeared first on MyMedicPlus.

New concerns in the management of the disease with the Covid 19 pandemic have created a state of anxiety amongst expectant mothers.

New Delhi: The rising incidence of gestational diabetes in India and globally is a cause for global concern amongst clinicians and obstetricians. Prevalence of the condition is higher in the urban than the rural population in India. Established risk factors for GDM are a family history of diabetes, obesity, advancing maternal age, reduced physical activity, desk jobs, sedentary lifestyle, unhealthy eating habits, smoking and alcohol consumption, history of PCOD and associated factors such as hypertension.

Due to compromised fetal outcomes in the form of higher incidence of miscarriages, congenital birth defects, higher risk of preterm deliveries, acute respiratory distress and hyaline membrane disease, heart disease, complicated labour due to the large size of the foetus leading to a higher incidence of shoulder dystocia and a higher risk of caesarean sections, hypoglycaemia in the newborn, obesity and a higher incidence of diabetes in the newborn, prevention and active management of altered blood sugars imperative.

How COVID-19 pandemic has changed consultation, diagnosis of gestational diabetes

New concerns in the management of the disease with the COVID-19 pandemic have created a state of anxiety amongst expectant mothers.

The standard glucose tolerance test which was previously held as the gold standard for monitoring women with altered blood sugars has now taken the backseat. Prioritising on social distancing, reducing frequent visits to labs, now monitoring expectant mothers with fasting blood glucose and HbA1c (of 5.7) are now accepted contrary to the glucose tolerance test. Altered routine prenatal visits, lack of personal consultation with the obstetrician and a phobia to visit labs has modified the management criteria. Lifestyle management comprising healthy dietary habits and increased physical activity, regular home monitoring (self) of blood sugars and fortnightly video consultation, routine antenatal tests for maternal well-being with a proper genetic history of any congenital defects or history of consanguinity, an early ultrasound helps rule out the possibility of an extrauterine pregnancy (ectopic) and confirms a healthy heart activity by 5.5 weeks thus ruling out chances of a missed aborption. All expectant mothers are offered the option of prenatal screening for Down’s syndrome (blood tests like the NIPT and dual markers) at 12 weeks, quadruple markers at 14 to 16 weeks, an anomaly scan at 19 weeks and most importantly a fetal cardiac anomaly scan at 23 weeks. Patients prefer to visit stand-alone ultrasound clinics with prior appointments following all the Covid-19 precautions. A repeat ultrasound Doppler at 28 to 30 weeks to check for the interim growth possibility of fetal macrosomia is advisable. At 32 weeks again an HbA1c to monitor blood sugars is advisable with home charting. Known diabetics in pregnancy have to follow up closely with the diabetologist to adjust the dose of insulin. In case of preterm labour, a hospitalization with tocolytics and antenatal betamethasone injection to promote lung maturity is advisable, and should such patients progress to irreversible preterm labour then drugs such as magnesium sulphate are offered as an option after counselling the expectant mother for neuroprotection for the foetus. Delivering such patients is preferred in tertiary care centres where all facilities for neonatal care are available owing to the high incidence of hyaline membrane disease and acute respiratory distress syndrome. COVID-19 evaluation is mandatory for patients prior to admission. Each index case if affected with COVID-19 behaves differently and needs individually tailored treatment for her symptoms. Vertical transmission is not a reason to fear as it is seldom encountered. Commonly encountered heart defects are usually diagnosed early in pregnancy during the anomaly scans. Late-onset issues in infants of diabetic mothers could be macrosomia, fetal cardiomyopathy, cardiomegaly, acute respiratory distress with fetal hypoglycaemia which warrant intensive care.

Maternal issues such as a higher incidence of prolonged labour, obstructed labour, higher incidence of caesarean sections, the associated risk of hypertension, are observed. To avoid these, prevention is better than cure, and hence expectant mothers with a high risk of gestational diabetes with obesity or PCOD are advised monitored weight gain of not more than 7-8 kg. Close monitoring of blood sugars from the first trimester helps reduce the chances of fetal and maternal complications. The TDAP vaccine is offered to all mothers at 32 weeks.

In conclusion, we as physicians have to constantly tailor monitoring techniques, counsel expectant couples with close follow-ups to monitor fetal and maternal well-being. The COVID-19 precautions are here to stay till we see the end of the tunnel in this global pandemic.

The post Impact of COVID-19 pandemic on diagnosis and testing of gestational diabetes appeared first on MyMedicPlus.

As Diwali is around the corner, chances are high that one might indulge in deep-fried snacks and sugar-laden sweets. However, this unhealthy indulgence can impact people with diabetes. Several doctors have recommended a few tips or ways through, you can tackle the situation while indulging in your favourite foods.
According to a BeatO study, festivals adversely impact people’s blood-glucose levels, especially during Diwali. People with levels above 250 mg/dL (milligrams per decilitre) saw an almost 15 per cent rise while those having blood-glucose levels above 300 mg/dL had an 18 per cent increase. Typically, this trend continued until three days after Diwali as per insights based on its data of the last three years’ festive season, beginning on Durga Puja and ending with Diwali. Interestingly, this year Diwali is being celebrated on November 14, which coincides with World Diabetes Day.

“Indian festivals reflect our rich and diverse culture along with the celebration, colors, food, and happiness, and the positive impact of which cannot possibly be quantified. Whether an individual has a chronic health condition or not, it is important not to snatch away the joy of enjoying a festival and everything that it brings along,” Dr Bhavik Saglani, Diabetes Health Physician and Consultant at Mumbai’s Apollo Spectra Hospital, told IANSlife.

Dr Saglani added, “Festivals may involve fasting or feasting or in some instances a bit of both. Exercise routine usually takes a backseat and activity levels to tend to drop. It is a combination of the above that needs to be taken into consideration in individuals with diabetes. Ensuring good pre-festival sugar control, discussing with your physician whether or not fasting is advisable in your case, ensuring that sugary sweets and other carbohydrate-rich snacks are avoided or their portion size is limited, trying to compensate for all of it by ensuring your exercise routine does not take a back seat, keeping yourself well hydrated and ensuring regular home testing are some of the key steps to strike the right balance between enjoying a festival and managing diabetes. Extra care needs to be taken for those who are on insulin and those who have high sugar levels even prior to the festive period. There is a risk of hypoglycaemia (low sugar levels) or hyperglycemia (high sugar levels) due to one or more of the above mentioned factors and it is imperative to get a review with your treating physician prior to the festive period.”

According to Dr Sanjay Ingle, Zonal Pathologist, and Technical Head West India, Apollo Diagnostics, Pune, one must monitor their blood sugar levels in order to check the insulin dose before every meal. Not doing so can invite a lot of problems. “Similarly, those with type 2 diabetes are suggested to go for intensive insulin therapy under the doctor’s supervision. Moreover, even self-monitoring of blood glucose (SMBG) is essential in these people too. There are some people who are on less intensive insulin therapy and they tend to monitor it little or not at all, this is an ineffective practice, as well-controlled patients need monitoring of glucose levels to avoid hypoglycemia, and poorly controlled patients need to control it properly.”

“Your doctor will recommend changes in the diet, will ask you to do physical activity, and opt for medication after assessing your blood sugar levels. You will have to work in sync with your doctor to help yourself get back on track. Even if it is festive season or no, make sure you monitor your blood sugar levels and manage diabetes,” explains Dr Ingle.

For those who are not fasting but prefer to feast on the variety of foods that are served during festivals, there are certain important measures to be taken to ensure the blood sugar control does not go haywire, adds Dr Nishant Singh, Consultant, General Medicine and Diabetology, Meddo Clinic.

One can follow these simple measures:

• Break your meals into smaller portions of about 4 to 5 times every day, instead of 3 large meals through out the day. This can keep your blood sugar levels more stable, while you are nourished adequately.
• You can opt for healthy snacking options such as nuts, olives or a piece of fruit. You could replace traditional sweets with such healthy options to ensure healthy is not compromised in celebrations. Ensure keeping your body hydrated and nourished. However, you can have a small piece of sweets.
• Consider consuming good-quality dark chocolate instead of milk chocolate as they consist of less sugar. One should try and avoid sugary drinks and replace them with either water, sugar free lime juice or even a small tumbler of tender coconut water would be a good choice.
• White rice is a favorite of many however, ones with diabetes should try and avoid it as it has a high glycaemic index and glycaemic load and can increase your blood sugars drastically. Instead, consume brown rice or whole grains as these keep the sugar levels a lot better controlled.
• Bakery foods such as biscuits and cakes must be avoided completely. Avoid deep-fried foods such as samosas and pakodas.
• One should try and avoid excessive indulgence in alcohol during festival seasons. Alcohol also contains a large quantity of sugar in it and can increase blood sugar levels.

Indian festivals are joyous occasions that are marked by the serving of sweets and savoury items. Those with diabetes can still enjoy these festivals, provided certain simple measures are followed to keep the blood sugar levels under check.

The post Follow these 7 tips to manage diabetes during festive season appeared first on MyMedicPlus.

Past studies have suggested that impaired biosynthesis could be the result of diverse mutations that hinder the foldability of proinsulin.

New York: The evolution of insulin in vertebrates — including humans — has encountered a roadblock, limiting its ability to adapt to obesity and thereby rendering most people vulnerable to Type 2 diabetes, a significant research has claimed.

Scientists from Indiana University (IU), University of Michigan and Case Western Reserve University determined that the sequence of insulin has become entrenched at the edge of impaired production — an intrinsic vulnerability unmasked by rare mutations in the insulin gene causing diabetes in childhood.

Insulin is produced by a series of highly specific processes that occur in specialised cells called beta cells.

A key step is the folding of a biosynthetic precursor, called proinsulin, to achieve the hormone’s functional three-dimensional structure.

Past studies have suggested that impaired biosynthesis could be the result of diverse mutations that hinder the foldability of proinsulin.

“Biological processes ordinarily evolve to be robust, and this protects us in the majority of cases from birth defects and diseases. Yet, diabetes seems to be an exception,” said Michael Weiss, Distinguished Professor at IU School of Medicine.

The group discovered that even the slightest variation of the insulin-sequencing process not only impairs insulin folding (and eventual insulin secretion) but also induces cellular stress that leads to beta cell dysfunction and eventually permanent damage.

The study, published in the Proceedings of the National Academy of Sciences, highlights the importance of folding efficiency as a critical but hidden factor in the evolution of insulin over the past 540 million years.

Humans have evolved to be vulnerable to diverse mutations in the insulin gene and that this vulnerability underlies a rare monogenic form of diabetes and provides an evolutionary backdrop to the present obesity-related diabetes pandemic.

“The authors highlight the fact that the insulin gene has been susceptible throughout evolution to mutations that impair insulin’s function or stress beta cells,” said Barbara Kahn from Harvard Medical School.

“As we approach the 100th anniversary of the discovery of insulin, these elegant observations might lead to a better understanding of the pathogenesis of Type 2 diabetes”.

The group will work to fully define the sequence determinants that make proinsulin foldable in beta cells.

The post Diabetes risk increase among humans as evolution of insulin hits roadblock appeared first on MyMedicPlus.

Taking care of your diet and lifestyle could go a long way in healthy diabetes management.

• Diabetics should eat at regular intervals
• Diabetics need to keep their calorie intake in check
• Diabetics should refrain from simple carbs

If we were to count the most common health conditions of the millennium, diabetes would perhaps be somewhere on the top of the charts. Diabetes mellitus is a metabolic disease that is characterised by blood sugar fluctuations. Afflicting over millions of people across the world, diabetes stands as one of the biggest threats for people both young and old as it has no known cure. It is believed that the condition cannot be reversed, but there are plenty of measures you can take to manage the condition and its symptoms. Taking care of your diet and lifestyle could go a long way in healthy diabetes management.

Many nutritionists vouch for including seasonal fruits and vegetables to one’s diet. Guava is one of our most favourite winter fruits that we can have in any form and anytime of the day, and guess no one is complaining because it is so healthy too. Guava is a treasure trove of antioxidants, vitamins and minerals. Moreover, it is a very good addition to a diabetes diet too. It is replete with good quality fibres and also has a very low Glycaemic Index of 15. In other words, eating guavas may not have a detrimental effect on your blood sugar levels, as they do not get digested too soon and enable gradual release of sugar into the bloodstream.

Including chunks of crunchy guava in your salad could not only enhance the flavour and texture of your salad but also make it a very healthy meal option, if you happen to be a diabetic. And why just stick to guava, there are plenty of diabetic-friendly foods around you that could do the trick.

(Also Read: Diabetes Diet: 5 Foods And Herbs That May Help Regulate Blood Sugar Levels)

This salad by celebrity chef Vikas Khanna comes with the goodness of guavas, paneer, moong dal sprouts, apples, tamarind pulp and black salt. There, we saw you slurping!

Almost all of these ingredients are high in fibre and in protein, both of which are crucial for diabetes management. The recipe also uses jaggery, which is said to be a healthy alternative of sugar. But if you are wary of using jaggery, you may as well skip it. In fact, if you happen to mix and match things, rule out some ingredients, add some of your own you can do so- it is your salad after all!

The post Diabetes? This Winter Salad By Chef Vikas Khanna Is Ideal For Your Diabetes Diet appeared first on MyMedicPlus.

The Smart Diabetes Management Market 2020 Global Report serves as a document containing aggregate information, which promotes and assists in the estimation of all aspects of the Smart Diabetes Management Market. It gives an image of the base and framework of the Smart Diabetes Management market, which describes its favorable or restrictive points for global and regional growth. It describes the current situation of the Smart Diabetes Management market by examining in depth various producers, unions, organizations, suppliers and industries under the Smart Diabetes Management market. In addition, the Global Smart Diabetes Management Market 2020 report provides meaningful information on segmentation, distribution network, estimated growth trends, monetary and trading terms, and many other crucial components relevant to the Smart Diabetes Management market.

The size of the global Smart Diabetes Management market is expected to grow in the forecast period from 2020 to 2027, with a CAGR of XX. x% over the forecast period from 2020 to 2027 and is expected to reach XXX. X million by 2027, starting at XXX. X million in 2019.

Global Smart Diabetes Management Market competition by Top Key Players: F. Hoffmann-La Roche, Medtronic, Dexcom, Insulet Corporation, Abbott, Jiangsu Delfu medical device, DIAMESCO, LifeScan, Glooko, GlucoMe.

Segmentation: The report has been separated into separate categories, such as product type, application, end user, and region. Each segment is evaluated based on the CAGR, share and growth potential. In the regional analysis, the report highlights the prospective region, which should generate opportunities in the global Smart Diabetes Management market in the years to come. This segment analysis will surely prove to be a useful tool for readers, stakeholders and market participants to get a full picture of the Smart Diabetes Management global market and its growth potential in the years to come.

Global Smart Diabetes Management Market Segmentation:

On the Basis of Type:
Type 1 Diabetes

Type 2 Diabetes

On the Basis of Application:
Hospital

Specialty Diabetes Clinics

Home

Regions Covered in the Global Smart Diabetes Management Market:
The Middle East and Africa
North America
South America
Europe
Asia-Pacific

Get Special Discount:

Analysis of the competitive landscape: The competitive landscape is an essential aspect that all key players must know. The report highlights the competitive scenario of the Smart Diabetes Management global market for competition nationally and globally. Market experts also presented an overview of all major players in the global Smart Diabetes Management market, taking into account key aspects such as the areas of operation, production and the product portfolio. In addition, the companies in the report are studied based on key factors such as company size, market share, market growth, revenues, production volume and profits.

Scope of the report: – This report describes the global Smart Diabetes Management market, in particular in North America, South America, Africa, Europe and Asia-Pacific, and the Middle East. This report segments the market based on producers, regions, type and use. In the next time, Smart Diabetes Management will have good demand, although the value may fluctuate due to the rapid transformation in the availability of raw materials and other resources.

Research methodology

The report includes an in-depth study of various aspects of the Smart Diabetes Management market. The overall research and analysis is derived from primary and secondary research. The main sources include interviews, surveys and observations of seasoned analysts, and secondary sources cover reputable paid sources, trade journals and databases of industry organizations. Other research methods include SWOT analysis and the use of Porter’s five-force model to extract growth potential from the market.

Table of Content (TOC):

Chapter 1 Introduction and Overview

Chapter 2 Industry Cost Structure and Economic Impact

Chapter 3 Rising Trends and New Technologies with Major key players

Chapter 4 Global Smart Diabetes Management Market Analysis, Trends, Growth Factor

Chapter 5 Smart Diabetes Management Market Application and Business with Potential Analysis

Chapter 6 Global Smart Diabetes Management Market Segment, Type, Application

Chapter 7 Global Smart Diabetes Management Market Analysis (by Application, Type, End User)

Chapter 8 Major Key Vendors Analysis of Smart Diabetes Management Market

Chapter 9 Development Trend of Analysis

Chapter 10 Conclusion

Place a Direct Order Of this Report:

For Any special requirements about this report, please let us know and we can provide custom reports.

Note – In order to provide a more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

In the event that you don’t find that you are looking in this report or need any particular prerequisites, please get in touch with our custom research team at sales@contrivedatuminsights.com

The post Smart Diabetes Management Market By Major key Players Abbott, Jiangsu Delfu medical device, DIAMESCO, LifeScan appeared first on MyMedicPlus.

The post First-of-its-kind diabetes centre opens in Dubai appeared first on MyMedicPlus.

14 out of 630 patents, with no history of diabetes during COVID-19 treatment, were diagnosed with diabetes at follow up clinics.

CHENNAI: Newly found diabetes among COVID-19 recovered patients is becoming a serious health condition, observed doctors in Chennai. Out of the 630 people who visited the post-COVID follow up clinic at the Rajiv Gandhi Government General Hospital, doctors said 14 people were diagnosed with diabetes.

This phenomenon has been observed worldwide lately by experts, who are trying to understand whether and how COVID-19 might be triggering diabetes among those who didn’t have the disease before. A senior doctor in-charge of the follow-up clinic said that none of the patients had diabetes during their stay at the hospital and it is only found weeks or even a month after their recovery.

“While most people who returned to the hospital with poor health conditions were aged above 45, the people with newly found diabetes post-recovery were just aged between 40-45,” the doctor said.

The doctor said that while breathing issues and myalgia (muscle pain) have been the common health condition that majority of people have come up with, the diabetes is something new. “Sugar checks are mandatory as part of COVID checks. Even for diabetes patients, insulin shots are given to keep sugar in check during treatment,” said that doctor, adding that the reason for people developing diabetes post-COVID recovery is not known.

The medico added that the patients are given insulin shots and are directed to undergo routine treatment for diabetes. Doctors said that the hospital keeps check of the patients’ health condition daily for 14 days after discharge and most patients returned back with health conditions after two weeks.

Steroids a possible reason?

Dr V Mohan, chairman, Dr Mohan’s Diabetes Specialities Centre, said high doses of steroids during the COVID-19 treatment could be a reason for sugar levels going up post-discharge. “Initially, patients are given intravenous steroids and subsequently, it is reduced to oral doses before the doses are stopped. Sugar levels too are supposed to reduce after this but some people without any diabetes too show high sugar levels post discharge,” Dr Mohan said.

He said that it is unknown whether COVID -19is directly involved in the increase in sugar levels but steroids could possibly have an impact. Various studies globally have highlighted that the immunosuppressive tendencies of steroids facilities in sugar levels are going uncontrolled among patients.

Dr Subramanian Swaminathan, Infectious Diseases Specialist at Gleneagles Global Health City said this trend of patients developing diabetes is seen worldwide. “Whether COVID-19 has caused diabetes or unmasked diabetes, we don’t know yet,” he said.

Dr Swaminathan said that even patients with mild COVID are developing diabetes later on. “In such a scenario, we can’t say the medicine is solely responsible for causing diabetes. Maybe it just has some part to do with this,” he said. Dr Swaminathan added that chronic fatigue syndrome, intermittent fever and inflammatory syndrome are widely observed among patients post-recovery.

“Unless we follow up on more patients, we won’t know the exact reasons for health complications. It is a good initiative to have follow up clinics and we need to expand it,” he said.

The post Patients developing diabetes post coronavirus recovery a growing concern appeared first on MyMedicPlus.

Source – https://www.medicalnewstoday.com/

Researchers have uncovered new clues to the mystery of how the gut’s nervous system affects glucose metabolism in the rest of the body. Their findings could lead to new treatments for type 2 diabetes.

The post Study reveals the role of our ‘second brain’ in diabetes appeared first on MyMedicPlus.

Forty patients were give home-monitoring devices that regularly send data to the Dubai Diabetes Centre.

Diabetics need regular medical check-ups to prevent complications. But what if a patient could get all the monitoring done at home and doctors could receive updates in real-time? Experts in Dubai have started a study that could determine how virtual check-ups and telemonitoring could benefit people with diabetes. 

The Dubai Diabetes Centre (DDC) on Tuesday announced that they are currently testing a telemonitoring system, with 40 patients selected for the research. Home monitoring devices, a smart pill box, mobile technologies and a software were all provided to track daily patient data, allowing specialists to plan interventional strategies. 

“Diabetes requires one to have regular follow-ups to avoid complications. In general, over time, patient compliance reduces and they tend to miss follow-up appointments,” explained Dr M. Hamed Farooqi, director of the DDC.

“Even a gap of three to six months with no follow-ups can be severely detrimental to diabetic patients, especially those with other comorbidities. Therefore, the aim of this study is to provide diabetics with home monitoring devices and regularly receive data from them so that we can keep a close eye on their condition.”

The study shall be carried out until the end of December and it is expected to be completed by early next year, he added. Once done, the centre will evaluate how effective telemonitoring is and whether it should incorporated within the system.

How the study works

Each patient taking part in the DDC study was given four home-monitoring devices: A blood pressure monitor, a blood glucose monitor, heart rate monitor and pulse oximeter. There were also provided with a pill box, which beeps every day at the time their medicine needs to be taken.

If they don’t take the medicine on time or miss the medicine, the data is immediately sent to the centre.

Patients were also given a mobile phone. They need to place this phone close to their monitoring devices whenever they use them. 

“The mobile has the software which captures all the patient data and automatically sends it to our centre. In the data room, the data gets automatically triaged as green, yellow and red based on artificial intelligence,” Dr Farooqi explained.

“Green means the results are fine, yellow means the readings are slightly abnormal, and red means the patient needs intervention. If the data falls under the yellow category, the patient is automatically sent a push notification, which informs him that the results are slightly abnormal, and therefore the patient needs to take the necessary measures as already advised by healthcare providers. 

“If the data falls under the red category, the patient gets a call from DDC and the healthcare provider can provide a phone consultation or request them to visit the centre for further consultation.”

At the end of every week, a doctor receives a comprehensive patient report, said Dr. Farooqi. “This kind of real-time monitoring helps the patient stay on track and ensures there is no time-gap in terms of physical consultation, which means complications can be greatly reduced.”

Currently, a video call feature is also being tested for the study. 

Healthcare innovation

The study was announced during the visit of Humaid Al Qutami, director-general of the Dubai Health Authority, to the centre.

Al Qutami said: “The DHA strongly focuses on technology to improve patient care and drive down costs of healthcare. In the current healthcare climate, globally, there has been a surge in the importance of telehealth. 

“At the DHA, we aim to continue employing various technologies that fit the nuances of the healthcare landscape in the emirate…We are keen to continue medical research, especially in the field of healthcare and technology, to help empower patients and improve patient care and compliance.”

Currently, diabetics have home-monitoring devices which they use to check their blood sugar and blood pressure. They store the data in the devices and whenever they go for their follow-up appointment – which is typically every two to three months – the endocrinologist reviews the data in one go. During this period, if the numbers are higher than usual, the patient has to contact the DDC and schedule a phone consultation or an appointment.

The post Dubai explores real-time monitoring, virtual check-ups for diabetics appeared first on MyMedicPlus.

Ertugliflozin is the most recent SGLT-2 inhibitor approved by the FDA. Recent studies, such as DAPA-HF and the EMPEROR-Reduced trial, have shown that SGLT-2 inhibitors have significant cardiovascular benefits in patients with and without type 2 diabetes. SGLT-2 inhibitors are now recommended to add-on to metformin in patients with type 2 diabetes and evidence of HFrEF or CKD by the American Diabetes Association. With the FDA now mandating cardiovascular safety evaluation be included in trials for new antihyperglycemic agents, VERTIS CV looked at the long-term renal and cardiovascular effects of Ertugliflozin in patients with type 2 diabetes. 

This randomized, placebo-control trial aimed to show that ertugliflozin was non-inferior to placebo concerning the study‘s primary endpoint. This study’s primary endpoint was a composite of MACE, including death from cardiovascular causes, nonfatal MI, or nonfatal stroke. The critical secondary endpoints were a composite of HF hospitalization and death by cardiovascular causes and the composite renal outcome, including renal replacement therapy, serum creatinine doubling, or death from renal causes. A test for superiority was to be conducted for the critical secondary endpoints if non-inferiority was proven in the primary endpoint. To be included in the study, patients with type 2 diabetes (A1c between 7 and 10.5%) had to be ≥ 40 years of age with atherosclerotic cardiovascular disease. Patients were excluded if they had an eGFR < 30 mL/min/1.73m2, a history of diabetic ketoacidosis, or type 1 diabetes. 

Patients were randomized 1:1:1 into study arms receiving either 5 mg or 15 mg of ertugliflozin or placebo on top of the patient‘s standard diabetes therapy. Baseline characteristics were balanced in all three of the arms. The mean duration of the study was 3.0 years, with the mean follow-up period being 3.5 years. 

A total of 8246 patients were enrolled in the trial, 5499 patients in the combined ertugliflozin arms, and 2747 patients in the placebo arm. MACE’s primary endpoint was reached in 11.9% of patients in the combined ertugliflozin arms and 11.9% in the placebo group (HR 0.97; 95.6% CI 0.85 – 1.11; p<0.001), demonstrating non-inferiority. In the composite secondary endpoints analysis, patients in the ertugliflozin group had a 12% lower risk of death by cardiovascular cause or hospitalization for heart failure, though not significant (HR 0.88; 95.8% CI, 0.75 – 1.03; p=0.11). A 19% lower risk of the composite renal outcomes was also seen in the combined ertugliflozin arms, though not significant (HR: 0.81, 95.8% CI 0.63-1.04). Of the remaining secondary endpoints, the risk of hospitalization for heart failure was 30% lower in the combined ertugliflozin arms though it was not tested for statistical significance (95% CI 0.54-0.90). At week 18, patients taking ertugliflozin had a lower mean reduction in A1c than patients in the placebo arm. A mean difference of -0.70% and -0.72% was seen in the 5 mg ertugliflozin and 15 mg ertugliflozin arms, respectively, and a difference of -0.22% was seen in patients who received placebo. Adverse events leading to death or permanent discontinuation of the trial regimen did not differ significantly between the groups. Rates of urinary tract infections and genital mycotic infections in both males and females were significantly higher in patients taking ertugliflozin as compared to placebo (p=0.03, p <0.001 and p <0.001, respectively) 

Ertugliflozin was found to be non-inferior to placebo concerning MACE. Still, it did not show superiority to placebo in risk reduction of composite renal outcomes or the composite cardiovascular outcomes of hospitalization for heart failure or death by cardiovascular cause. Potential explanations of why ertugliflozin did not reach significance in the critical secondary outcomes include the increased intensity of secondary preventive strategies over the past few years and differences among the SGLT-2 class agents. Though the composite renal outcomes were not met, for other agents in this class, each trial had different definitions for their renal endpoints. Further analysis could be done by modifying the renal endpoints to compare the outcome to other SGLT-2 inhibitors better.  

Practice Pearls: 

• Ertugliflozin was non-inferior to placebo in its effects on MACE, including death from cardiovascular causes, nonfatal MI, or nonfatal stroke. 
• There was no difference in the critical secondary outcomes in the combined ertugliflozin and placebo arms. 
• Further study can be done to better compare VERTIS CV renal outcomes to that of other SGLT-2 inhibitors. 

The post The Long-term Cardiovascular Effects of Ertugliflozin in Type 2 Diabetes appeared first on MyMedicPlus.